The Pharma Data

JUNE 7, 2022

(Nasdaq: BIIB) — Biogen and Alectos Therapeutics have entered into a license and collaboration agreement to develop and commercialize a novel preclinical selective GBA2 inhibitor, AL01811, which has first-in-class potential as an oral disease modifying treatment for patients with Parkinson’s disease (PD).

Licensing 40

Licensing Licensing Small Molecule Disease 40

The Pharma Data

JANUARY 5, 2021

Durham, North Carolina-based Ribometrix announced a strategic collaboration deal with Genentech , a Roche company, to identify and advance novel RNA-targeted small molecule therapeutics. This is because many proteins do not have small-molecule binding sites. This is not the first deal for RNA therapeutics for Genentech.

RNA 52

RNA Small Molecule DNA Licensing 52

The Pharma Data

OCTOBER 26, 2020

27, 2020 /PRNewswire/ — Aridis Pharmaceuticals, Inc. ” Panel: Direct Antivirals and Other Agents Against SARS-CoV2 Virus Date: Wednesday, October 28, 2020 Time: 10:30AM- 11:50AM ET. AR-711 is an in-licensed mAb that is directed against the receptor binding domain of the SARS-Cov 2 virus.

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

New Drug Approvals

SEPTEMBER 29, 2024

link] 01 Aug 2022 Cortexyme is now called Quince Therapeutics You need to be a logged in or subscribed to view this content This small molecule is an orally available protease inhibitor targeting the lysine proteases of the periodontal pathogen Porphyromonas gingivalis. Cortexyme’s approach is based on the theory that P.

Small Molecule 62

Small Molecule DNA Disease Trials 62

The Pharma Data

FEBRUARY 4, 2021

3, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) announced financial results for the fourth quarter and full year ended December 31, 2020. AbbVie hosted an Immunology Strategic Update event on December 14, 2020 for members of the investment community. NORTH CHICAGO, Ill., Gonzalez , chairman and chief executive officer, AbbVie.

Production 52

Production Clinical Trials International Small Molecule 52

The Pharma Data

DECEMBER 13, 2020

14, 2020 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. RLY-1971 is a potent small molecule inhibitor of Src homology region 2 domain-containing phosphatase-2 (SHP2). . Relay Therapeutics to host conference call at 8:00 a.m. CAMBRIDGE, Mass., About RLY-1971.

Licensing 40

Licensing Licensing Clinical Trials Small Molecule 40

The Pharma Data

NOVEMBER 23, 2020

24, 2020 07:05 UTC. OSLO, Norway–( BUSINESS WIRE )– Ultimovacs ASA (“Ultimovacs”, ticker ULTIMO), today announced that Ton Berkien will join Ultimovacs’ management team as Chief Business Officer (CBO), effective December 1, 2020. Mr. Berkien is currently a board member of the Nordic Pharma Licensing Group.

Clinical Trials 52

Clinical Trials Small Molecule Pharmaceutical Companies Licensing 52

The Pharma Data

NOVEMBER 11, 2020

12, 2020 14:00 UTC. As an orally bioavailable small molecule with broad antiviral activity, SLV213 could be a valuable treatment to meet today’s urgent need to fight COVID-19 as well other life-threatening infectious diseases, such as Chagas disease, Ebola virus disease, and Nipah virus infection.”. About SLV213.

Treatment 52

Treatment Small Molecule Virus Pharmacokinetics 52

The Pharma Data

NOVEMBER 29, 2020

29, 2020 /PRNewswire/ — Ascentage Pharma (6855.HK), ” “The emergence of the PROTAC technology represents another breakthrough in the identification of small molecule drugs. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 inhibitors) in clinical trials for cancer treatment.

Licensing 40

Licensing Licensing Small Molecule Clinical Trials 40

The Pharma Data

JANUARY 17, 2021

“People living with LN are in need of an advanced therapy that quickly drives the disease into remission and mediates kidney damage,” said Peter Greenleaf, president and chief executive officer of Aurinia, in July 2020 when the FDA accepted the NDA to review. “We As a result, it stabilizes the podocyte in the kidney.

FDA 52

FDA Small Molecule Immune Response Hospitals 52

The Pharma Data

DECEMBER 2, 2020

In 2020, the American Cancer Society estimates there to be about 228,280 new cases of lung cancer in the country. The drug is a small-molecule inhibitor of the S. Vivlion holds an exclusive license to Goethe University of Frankfurt’s proprietary 3Cs technology for the production of next generation 3Cs CRISPR/Cas gRNA libraries.

Licensing 52

Licensing Licensing DNA Vaccine 52

The Pharma Data

OCTOBER 18, 2020

19, 2020 08:02 UTC. Inflection Biosciences Ltd is developing small molecule therapeutics for the treatment of cancer. The company’s pipeline was licensed from the Spanish National Cancer Research Centre (CNIO). Berk, MD, to its Board of Directors. About Inflection Biosciences.

Small Molecule 40

Small Molecule Clinical Development Clinical Trials Licensing 40

The Pharma Data

NOVEMBER 18, 2021

— Gilead Exercises Options to Arcus’s Anti-TIGIT Program (Domvanalimab and AB308), Etrumadenant (A2a/A2b Adenosine Receptor Antagonist) and Quemliclustat (Small Molecule CD73 Inhibitor) — — Arcus to Receive Option Payments Totaling $725 million — Gilead Lores,Inc. Nasdaq GILD) and Arcus Biosciences,Inc.

Research 52

Research Clinical Development Small Molecule Packaging 52

FDA Law Blog: Biosimilars

FEBRUARY 26, 2024

But in 2020, a Citizen Petition came along looking to upend FDA’s approach to strength. Boehringer Ingelheim submitted a Citizen Petition in December 2020 encouraging FDA to interpret the term “strength” under the BPCIA differently than the Agency does under the Hatch-Waxman Act. mL) in addition to Original Concentration Humira.”

FDA 59

FDA Biosimilars Production Regulations 59

The Pharma Data

NOVEMBER 8, 2020

9, 2020 /PRNewswire/ — Solid 9M business performance despite COVID-19 and generic Aczone challenges: Net Sales €613.8 Based on the solid year to date performance Almirall is reiterating its guidance for FY 2020. YTD September 2020. BARCELONA, Spain , Nov. MM (-3.7%; +4.3%

Licensing 52

Licensing Licensing Production Treatment 52

The Pharma Data

JANUARY 13, 2021

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions.

Pharmaceuticals 52

Pharmaceuticals Small Molecule Vaccine Protein Expression 52

The Pharma Data

DECEMBER 15, 2020

In late 2020, the effort received $200,000 in seed funding from the Baker Department of Cardiometabolic Health at the University of Melbourne’s medical school. Small Molecule Inhibitors. NMD670 is a first-in-class small molecule inhibitor of the muscle specific chloride ion channel, the ClC-1 ion channel.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

The Pharma Data

APRIL 27, 2021

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

OCTOBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. CHATHAM, N.J., 1 Noyce RS, et al.

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

The Pharma Data

OCTOBER 25, 2020

Both those serotypes are associated with invasive pneumococcal disease globally and are not otherwise in currently licensed conjugate vaccines for use in adults. Astellas Pharma , FibroGen and AstraZeneca presented 42 abstracts about Roxadustat at the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined congress.

Vaccine 52

Vaccine Clinical Trials Trials Virus 52

The Pharma Data

SEPTEMBER 9, 2020

The proposed agreement is intended to provide a supply of 200 million doses and an option to purchase additional 100 million doses, with deliveries starting by the end of 2020, subject to regulatory approval. Deliveries would be starting by the end of 2020, subject to clinical success and regulatory authorization.

Vaccine 52

Vaccine Clinical Trials Trials Government 52

The Pharma Data

SEPTEMBER 12, 2020

Pfizer Disclosure Notice: The information contained in this release is as of September 12, 2020. For a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report on Form 20-F filed with the SEC on March 31, 2020, which is available on the SEC’s website at www.sec.gov.

Vaccine 52

Vaccine Trials Clinical Trials Small Molecule 52

The Pharma Data

DECEMBER 12, 2020

12, 2020– AstraZeneca and Alexion Pharmaceuticals, Inc. AstraZeneca has developed a broad range of technologies, initially focused on small molecules and biologics and with a growing focus in precision medicine, genomics, oligonucleotides and epigenetics. As of 30 September 2020 , Alexion had gross assets of $17.5bn.

Regulations 75

Regulations International Disease Small Molecule 75

The Pharma Data

JANUARY 10, 2021

2020 was a remarkable year of progress for Ascendis reflecting the dedication and commitment of our employees worldwide as we made meaningful strides to achieve our vision, and meet or accelerate completion of our key milestones,” said Jan Mikkelsen, Ascendis Pharma’s President and Chief Executive Officer. . .

Clinical Trials 40

Clinical Trials Clinical Development Small Molecule Trials 40

The Pharma Data

NOVEMBER 5, 2020

. Trading under “OCUP” on the Nasdaq Capital Market to begin November 6, 2020. Conference Call and Live Webcast on Friday, November 6, 2020, at 11 AM Eastern Time. 05, 2020 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. , Concurrent $21.15 FARMINGTON HILLS, Mich.,

Clinical Trials 40

Clinical Trials Trials Production Small Molecule 40

The Pharma Data

AUGUST 3, 2021

Revenue growth was 12 percent when excluding effects of 2020 COVID-related stocking patterns, revenue from COVID-19 antibodies and recent business development. ” $ in millions, exceptper share data Second Quarter % 2021 2020 Change Revenue $ 6,740.1 $ 5,499.4 on a reported basis and increased to $1.87 on a non-GAAP basis.

Production 52

Production Marketing Research DNA 52

The Pharma Data

SEPTEMBER 9, 2020

Assuming clinical success, Pfizer and BioNTech are on track to seek regulatory review for BNT162b2 as early as October 2020 and, if regulatory authorization or approval is obtained, currently plan to supply up to 100 million doses worldwide by the end of 2020 and approximately 1.3 billion doses by the end of 2021.

Vaccine 52

Vaccine Clinical Trials RNA Trials 52

Agency IQ

OCTOBER 6, 2023

All products are received in one of two forms: A New Drug Application (or NDA, for pharmaceuticals) or a Biologics License Application (BLA, for biologics). There were 21 NMEs added to the FDA’s Purple Book , which provides information about all biological products licensed by the FDA. See AgencyIQ’s analysis of these changes here.

FDA 52

FDA Biosimilars Science Production 52

The Pharma Data

AUGUST 20, 2020

These results informed the selection of the BNT162b2 candidate for the pivotal Phase 2/3 global study in up to 30,000 participants that started in July 2020, which has to date enrolled more than 11,000 participants, including in areas with significant SARS-CoV-2 transmission. The information contained in this release is as of August 20, 2020.

Vaccine 52

Vaccine Clinical Trials Trials Immune Response 52

The Pharma Data

SEPTEMBER 15, 2020

On a non-risk adjusted basis, these opportunities collectively represent more than $15 billion (excluding 20vPnC) in potential incremental revenue for Pfizer from 2020 to 2025, as well as aggregate peak annual sales potential of $35 billion to $40 billion (including 20vPnC). Penta was well tolerated. Safety was consistent with published data.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

The Pharma Data

MARCH 4, 2021

Takeda and Ovid reported results from the Phase 2 ELEKTRA study in August 2020, in which soticlestat met its primary endpoint of reducing seizure frequency in pediatric patients with DS or LGS. Advancing New Treatment Options for DS and LGS Patients. selective GABA A receptor agonist.

Treatment 52

Treatment Clinical Trials Pharmaceutical Companies Trials 52

The Pharma Data

APRIL 27, 2021

due to COVID related stocking in Q1 2020 and low demand for cough and cold brands in Europe. Following the communication of our ESG strategy at the end of 2020 and embedding it into our business priorities, we have recently created the Sanofi Global Health Unit, dedicated to increasing access to 30 medicines considered essential by the WHO.

Vaccine 52

Vaccine Production FDA Disease 52

The Pharma Data

DECEMBER 20, 2020

Auxora is a potent and selective small molecule CRAC channel inhibitor that prevents CRAC channel overactivation. Graphite Bio licensed the product from Stanford University. The drug was approved by the FDA for acute treatment of migraine in adults in February 2020 and is marketed under the name Nurtec ODT.

Vaccine 52

Vaccine Trials Therapies Small Molecule 52

The Pharma Data

NOVEMBER 9, 2020

NEW YORK & MAINZ, GERMANY–(BUSINESS WIRE) November 9, 2020. Based on current projections we expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 The information contained in this release is as of November 9, 2020. Submission for Emergency Use Authorization (EUA) to the U.S.

Vaccine 40

Vaccine Clinical Trials Trials FDA 40

The Pharma Data

AUGUST 3, 2021

billion in comparison to the second quarter of 2020, driven by higher unit demand, partially offset by lower net selling prices. billion in the second quarter of 2020 driven by a difference in the timing of tax payments. Total product sales increased 3% for the second quarter of 2021 versus the second quarter of 2020.

Biosimilars 52

Biosimilars Production Treatment FDA 52

The Pharma Data

APRIL 23, 2021

Dostarlimab was discovered by AnaptysBio and licensed to TESARO, Inc., under a Collaboration and Exclusive License Agreement signed in March 2014. Such factors include, but are not limited to, those described in the Company’s Annual Report on Form 20-F for 2020 and any impacts of the COVID-19 pandemic. [i] Published 2018.

Therapies 40

Therapies Treatment Licensing Licensing 40

Agency IQ

NOVEMBER 3, 2023

For example, the common Lactobacillus genus of probiotics was reclassified into 25 different genera in 2020. What about when microbes are reclassified or renamed? Well, confusion tends to follow. That is why L. rhamnosus is no longer Lactobacillus rhamnosus but is instead Lacticaseibacillus rhamnosus.

Therapies 40

Therapies Science FDA Production 40